Research suggests that lymphocytes may serve as a negative predictive marker for chemotherapy in estrogen receptor-positive breast cancer. This finding could potentially lead to the development of new tools, such as ai-powered approaches, to reduce unnecessary chemotherapy in breast cancer care. The role of immune response and various markers, including lymphocytes, in predicting treatment outcomes for breast cancer is being explored in ongoing studies.